EA201390631A1 - Композиция микобактериальных антигенов - Google Patents

Композиция микобактериальных антигенов

Info

Publication number
EA201390631A1
EA201390631A1 EA201390631A EA201390631A EA201390631A1 EA 201390631 A1 EA201390631 A1 EA 201390631A1 EA 201390631 A EA201390631 A EA 201390631A EA 201390631 A EA201390631 A EA 201390631A EA 201390631 A1 EA201390631 A1 EA 201390631A1
Authority
EA
Eurasian Patent Office
Prior art keywords
composition
mycobacterial antigens
less
mycobacterial
antigens
Prior art date
Application number
EA201390631A
Other languages
English (en)
Other versions
EA027920B1 (ru
Inventor
Стефан Андре Жорж Годар
Амина Лаанан
Доминик Ингрид Лемуан
Original Assignee
Глаксосмитклайн Байолоджикалс С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксосмитклайн Байолоджикалс С.А. filed Critical Глаксосмитклайн Байолоджикалс С.А.
Publication of EA201390631A1 publication Critical patent/EA201390631A1/ru
Publication of EA027920B1 publication Critical patent/EA027920B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Abstract

Предложены иммуногенные композиции, содержащие М72-родственный антиген, причем электропроводность композиции составляет 13 мСм/см или меньше либо концентрация солей в композиции составляет 130 мМ или меньше, и их применение в медицине.
EA201390631A 2010-12-14 2011-12-14 Композиция микобактериальных антигенов EA027920B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42272310P 2010-12-14 2010-12-14
PCT/EP2011/072816 WO2012080369A1 (en) 2010-12-14 2011-12-14 Mycobacterium antigenic composition

Publications (2)

Publication Number Publication Date
EA201390631A1 true EA201390631A1 (ru) 2014-11-28
EA027920B1 EA027920B1 (ru) 2017-09-29

Family

ID=45346501

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201390630A EA027504B1 (ru) 2010-12-14 2011-12-14 Композиция микобактериальных антигенов
EA201390631A EA027920B1 (ru) 2010-12-14 2011-12-14 Композиция микобактериальных антигенов

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201390630A EA027504B1 (ru) 2010-12-14 2011-12-14 Композиция микобактериальных антигенов

Country Status (32)

Country Link
US (5) US9730992B2 (ru)
EP (4) EP3593813A1 (ru)
JP (2) JP5951634B2 (ru)
KR (3) KR20140029376A (ru)
CN (4) CN106822882A (ru)
AR (1) AR084285A1 (ru)
AU (2) AU2011343368C1 (ru)
BR (2) BR112013014599A2 (ru)
CA (2) CA2819298A1 (ru)
CO (2) CO6751287A2 (ru)
CY (1) CY1122187T1 (ru)
DK (3) DK2651437T3 (ru)
EA (2) EA027504B1 (ru)
ES (3) ES2567190T3 (ru)
HR (3) HRP20160362T1 (ru)
HU (3) HUE045766T2 (ru)
IL (2) IL226450A0 (ru)
LT (1) LT3023106T (ru)
ME (1) ME02380B (ru)
MX (2) MX344280B (ru)
MY (1) MY161412A (ru)
PL (3) PL2651436T3 (ru)
PT (2) PT2651436E (ru)
RS (1) RS54687B1 (ru)
SG (2) SG190731A1 (ru)
SI (3) SI3023106T1 (ru)
SM (1) SMT201600118B (ru)
TW (1) TW201305192A (ru)
UA (2) UA110806C2 (ru)
UY (1) UY33802A (ru)
WO (2) WO2012080369A1 (ru)
ZA (2) ZA201304015B (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5164830B2 (ja) 2005-04-29 2013-03-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 結核菌感染の予防または治療のための新規方法
MY161412A (en) 2010-12-14 2017-04-14 Glaxosmithkline Biologicals Sa Mycobacterium antigenic composition
HUE032409T2 (en) 2011-01-04 2017-09-28 Archivel Farma Sl Liposome preparation for treating or preventing tuberculosis
PT2802345T (pt) 2012-01-12 2018-04-24 Archivel Farma Sl Vacina mtb-c contra a asma
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
CN113046312A (zh) 2014-04-23 2021-06-29 朱诺治疗学股份有限公司 分离、培养和遗传工程改造用于过继治疗的免疫细胞群的方法
GB201513176D0 (en) 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
GB201522068D0 (en) * 2015-12-15 2016-01-27 Glaxosmithkline Biolog Sa Dried composition
JP7136777B2 (ja) 2016-12-07 2022-09-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 新規プロセス
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
GB2600653B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel methods
EP3717001A1 (en) 2017-12-01 2020-10-07 GlaxoSmithKline Biologicals S.A. Saponin purification
RU2728976C2 (ru) * 2018-03-22 2020-08-03 Зули Холдингз, Лтд. Липосомный состав и его получение
MX2021001129A (es) 2018-07-31 2021-07-02 Glaxosmithkline Biologicals Sa Metodo de purificacion de antigenos.
US20220339282A1 (en) 2018-11-29 2022-10-27 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
BR112021024363A2 (pt) 2019-06-05 2022-03-22 Glaxosmithkline Biologicals Sa Purificação de saponina
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
US20210069321A1 (en) 2019-09-09 2021-03-11 Glaxosmithkline Biologicals Sa Immunotherapeutic compositions
CA3161857A1 (en) 2019-11-22 2021-05-27 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
MX2022013855A (es) 2020-05-05 2022-11-30 Glaxosmithkline Biologicals Sa Dispositivos de mezcla de microfluidos y metodos de uso.
US20230234992A1 (en) 2020-06-05 2023-07-27 Glaxosmithkline Biologicals Sa Modified betacoronavirus spike proteins
WO2022122830A2 (en) 2020-12-09 2022-06-16 Glaxosmithkline Biologicals Sa Saponins
CN114034860A (zh) * 2021-11-01 2022-02-11 宁夏大学 一种结核分枝杆菌mtb39a蛋白抗体间接elisa检测方法及其试剂盒
WO2023242187A1 (en) 2022-06-15 2023-12-21 Glaxosmithkline Biologicals Sa Enzymatic modification of saponins
CN116120411B (zh) * 2022-12-07 2024-04-12 中国疾病预防控制中心传染病预防控制所 结核分枝杆菌蛋白抗原混合物、多抗原融合蛋白及编码基因和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DK0382271T3 (da) 1989-02-04 1995-05-01 Akzo Nobel Nv Tocoler som adjuvanser i vacciner
DE69405551T3 (de) 1993-03-23 2005-10-20 Smithkline Beecham Biologicals S.A. 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
CA2194761C (en) 1994-07-15 2006-12-19 Arthur M. Krieg Immunomodulatory oligonucleotides
UA56132C2 (ru) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиция вакцины (варианты), способ стабилизации qs21 по отношению к гидролизу (варианты), способ приготовления вакцины
IL123506A (en) 1995-09-01 2004-12-15 Corixa Corp Polypeptide compounds and preparations for immunotherapy and diagnosis of tuberculosis
ATE324445T1 (de) 1995-09-01 2006-05-15 Corixa Corp Verbindungen und verfahren zur diagnose von tuberkulose
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
GB9619613D0 (en) 1996-09-19 1996-10-30 Breed Automotive Tech An inflatable restraint for a vehicle
EP0859366A1 (en) 1997-02-12 1998-08-19 STMicroelectronics S.r.l. Associative memory device with optimized occupation, particularly for the recognition of words
KR20010006169A (ko) * 1997-04-08 2001-01-26 폴락 돈나 엘. 안정화된 사람 파필로마바이러스 제형물
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
AU753995B2 (en) 1998-04-07 2002-10-31 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
WO1999052549A1 (en) * 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
WO2001024820A1 (en) 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
ATE442866T1 (de) 2000-06-20 2009-10-15 Corixa Corp Fusionsproteine aus mycobakterium tuberculosis
AU8189501A (en) 2000-06-29 2002-01-08 Smithkline Beecham Biolog Vaccine composition
US7026465B2 (en) 2002-02-15 2006-04-11 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis
GB0411411D0 (en) 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
JP5164830B2 (ja) * 2005-04-29 2013-03-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 結核菌感染の予防または治療のための新規方法
EP2368568A1 (en) 2006-11-01 2011-09-28 Immport Therapeutics, INC. Compositions and methods for immunodominant antigens
CA2687632C (en) 2007-05-24 2013-01-15 Glaxosmithkline Biologicals S.A. Lyophilised antigen composition
CA2707483A1 (en) 2007-11-30 2009-06-11 Wolfgang Fraunhofer Protein formulations and methods of making same
KR100955470B1 (ko) * 2008-01-09 2010-04-30 대한민국(관리부서 질병관리본부장) 탄저 방어 항원의 제조 방법
US8409901B2 (en) 2008-03-11 2013-04-02 The Royal Institution For The Advancement Of Learning/Mcgill University Low temperature wafer level processing for MEMS devices
GB0910045D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB201008512D0 (en) 2010-05-21 2010-07-07 Health Prot Agency Mycobacterial antigen composition
IT1400834B1 (it) 2010-07-07 2013-07-02 Aero Sekur S P A Metodo e sistema per l'atterraggio di emergenza di un veicolo, come un elicottero o simili.
MY161412A (en) 2010-12-14 2017-04-14 Glaxosmithkline Biologicals Sa Mycobacterium antigenic composition
GB201400819D0 (en) 2014-01-17 2014-03-05 Sec Dep For Health The Mycobacterial antigen composition

Also Published As

Publication number Publication date
EP3593813A1 (en) 2020-01-15
PT3023106T (pt) 2019-11-04
US20130287809A1 (en) 2013-10-31
KR20190022897A (ko) 2019-03-06
AU2011343367A1 (en) 2013-07-11
SI2651437T1 (sl) 2016-05-31
SI3023106T1 (sl) 2019-11-29
CO6751288A2 (es) 2013-09-16
CA2819298A1 (en) 2012-06-21
US9730992B2 (en) 2017-08-15
US20190183998A1 (en) 2019-06-20
UA110806C2 (ru) 2016-02-25
JP2013545783A (ja) 2013-12-26
KR101951894B1 (ko) 2019-02-26
PL3023106T3 (pl) 2019-12-31
CO6751287A2 (es) 2013-09-16
EA201390630A1 (ru) 2013-12-30
KR20130124525A (ko) 2013-11-14
HRP20191843T1 (hr) 2019-12-27
UA110118C2 (ru) 2015-11-25
IL226448A0 (en) 2013-07-31
EP2651437A1 (en) 2013-10-23
SMT201600118B (it) 2016-07-01
MX2013006818A (es) 2013-08-26
AU2011343368C1 (en) 2015-12-24
RS54687B1 (en) 2016-08-31
MX344706B (es) 2017-01-03
CN103260642B (zh) 2018-03-16
CN103249431A (zh) 2013-08-14
ES2574403T3 (es) 2016-06-17
JP2014505036A (ja) 2014-02-27
SG190731A1 (en) 2013-07-31
EA027504B1 (ru) 2017-08-31
MY161412A (en) 2017-04-14
WO2012080369A1 (en) 2012-06-21
ME02380B (me) 2016-06-20
US10441648B2 (en) 2019-10-15
ZA201304014B (en) 2017-04-26
EP2651436A1 (en) 2013-10-23
EP2651437B1 (en) 2016-02-10
EP3023106B1 (en) 2019-07-31
ZA201304015B (en) 2018-12-19
CN106822883A (zh) 2017-06-13
AU2011343368A1 (en) 2013-07-11
SI2651436T1 (sl) 2016-07-29
JP5951634B2 (ja) 2016-07-13
ES2748651T3 (es) 2020-03-17
LT3023106T (lt) 2019-10-25
CA2819297A1 (en) 2012-06-21
PL2651437T3 (pl) 2016-07-29
DK2651437T3 (en) 2016-05-02
UY33802A (es) 2012-07-31
HUE027932T2 (en) 2016-11-28
BR112013014599A2 (pt) 2016-09-27
ES2567190T3 (es) 2016-04-20
IL226450A0 (en) 2013-07-31
PL2651436T3 (pl) 2016-10-31
PT2651436E (pt) 2016-06-08
AU2011343368B2 (en) 2015-08-20
DK3023106T3 (da) 2019-09-30
US20130280289A1 (en) 2013-10-24
IL226448A (en) 2017-09-28
MX2013006819A (es) 2013-08-26
US20160220656A1 (en) 2016-08-04
CY1122187T1 (el) 2020-11-25
JP5951633B2 (ja) 2016-07-13
MX344280B (es) 2016-12-09
EP3023106A1 (en) 2016-05-25
HRP20160362T1 (hr) 2016-05-06
HUE045766T2 (hu) 2020-01-28
CN103249431B (zh) 2016-11-02
US20180071378A1 (en) 2018-03-15
AU2011343367B2 (en) 2015-05-21
SG190937A1 (en) 2013-07-31
EP2651436B1 (en) 2016-03-30
AR084285A1 (es) 2013-05-08
CN106822882A (zh) 2017-06-13
TW201305192A (zh) 2013-02-01
DK2651436T3 (da) 2016-06-20
WO2012080370A1 (en) 2012-06-21
BR112013014598A2 (pt) 2017-09-19
KR20140029376A (ko) 2014-03-10
CN103260642A (zh) 2013-08-21
HUE028452T2 (en) 2016-12-28
EA027920B1 (ru) 2017-09-29
HRP20160606T1 (hr) 2016-07-01
US9352030B2 (en) 2016-05-31

Similar Documents

Publication Publication Date Title
EA201390631A1 (ru) Композиция микобактериальных антигенов
CY1119918T1 (el) Συνθεσεις γαμμα-υδροξυβουτυρικου και η χρηση τους για την αντιμετωπιση διαταραχων
CY1120413T1 (el) Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
EA201300323A1 (ru) Материалы и способы улучшения функции желудочно-кишечного тракта
CY1118680T1 (el) Φαρμακευτικη συνθεση
TR201802380T4 (tr) Benzonaftiridin içeren aşılar.
NZ606589A (en) 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof
EA201390682A1 (ru) Спирооксиндольные антагонисты mdm2
TN2012000512A1 (en) Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
EA201390145A1 (ru) Конъюгаты, частицы, композиции и связанные с ними способы
EA201370018A1 (ru) Составы рифаксимина и их применение
EA201390660A1 (ru) Модифицированные никотиновые соединения и связанные способы
EA201190285A1 (ru) Иммуногенные композиции, имеющие низкую концентрацию хлорида натрия
EA201500054A1 (ru) Аттенуированные вакцины против streptococcus suis и способы их получения и применения
EA201201324A1 (ru) Профилактика колоректального и желудочно-кишечного рака
EA201291200A1 (ru) Кожные кондиционирующие композиции, содержащие 12-гидроксистеариновую кислоту
EA201400827A1 (ru) Материалы и способы лечения диареи
EP2591090A4 (en) CERAMIC LIKE GLYCOLIPIDE ASSOCIATED BACTERIAL VACCINES AND USES THEREOF
BR112013033544A2 (pt) dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicos
CY1118570T1 (el) Νεα συνθεση αλφαιντανυλης για την αγωγη του οξεος πονου
BR112015020079A2 (pt) composições para cuidado oral
BR112014013327A2 (pt) composições para cuidado oral
EA201291208A1 (ru) Композиция для ухода за волосами
BR112015020053A2 (pt) composições para cuidado oral
CY1117640T1 (el) Αντιγονικη συνθεση μυκοβακτηριου

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM